MedTrace Logo

Study on the Use of the Insulin Pump Tandem X:2 With Control IQ Algorithm - Update

NCT05118945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-09-19

No results posted yet for this study

Summary

The aim of this observational clinical trial is to obtain data on the safety, efficacy and satisfaction of the Tandem T:Slim X:2 Pump System in patients with type 1 diabetes.

Conditions

Interventions

DEVICE

Insulin pump Tandem: t:slim X2

Insulin pump with Hybrid-Closed Loop - Modus. The insulin pump t:slim X2 from the manufacturer Tandem, in cooperation with the glucose sensor DexCom G6, has the option of using an algorithm called "control IQ", which controls the insulin delivery semi-automatically by means of an MPC algorithm. For this purpose, the insulin basal delivery can be increased or decreased by the system. Furthermore, automatic bolus deliveries, which are possible in the amount of up to 60% of a manual correction, can be delivered.

Sponsors & Collaborators

  • Kinderkrankenhaus auf der Bult

    lead OTHER

Principal Investigators

  • Torben Biester, Dr. · Hospital for Children and Adolescents AUF DER BULT

Eligibility

Min Age
6 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2021-12-28
Completion
2021-12-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05118945 on ClinicalTrials.gov